Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "ISA"

1071 News Found

Punita Lal Joins Lupin Board as Additional Director
People | May 18, 2025

Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India


JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
News | May 16, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25


Briefs: Zydus and CuraTeQ Biologics
Drug Approval | May 14, 2025

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA


SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
News | May 03, 2025

SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification

This significant milestone enhances our global regulatory standing


Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
Drug Approval | April 28, 2025

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited


CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein


Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
News | April 24, 2025

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience


GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
News | April 19, 2025

GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed


Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies
News | April 15, 2025

Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies

Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches


Biocon Biologics secures market entry date for Yesafili in US
News | April 15, 2025

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions